May 10, 2019
FDA lists Sunovion’s, PsychoGenics’s SEP-363856 as breakthrough therapy for the treatment of schizophrenia
FDA) has granted Breakthrough Therapy Designation forSEP-363856, a novel agent for the treatment of people with schizophrenia.